Patent intelligence · US
US 12358892
Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders
Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders
Patent details — US 12358892
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 15, 2025
- Expiration
- Jul 10, 2045
- Applicant
- Miralogx LLC
- Claims
- 2
- CPC classes
- A61P, A61P29/00, A61P35/00
Quick answer
US 12358892 (Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders) is held by Miralogx LLC. Status: granted. Granted Jul 15, 2025. Expires Jul 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Miralogx LLC
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P29/00, A61P35/00
More from Miralogx LLC
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 12358892?
US 12358892 (Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders) is held by Miralogx LLC. Status: granted. Granted Jul 15, 2025. Expires Jul 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12358892?
Miralogx LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 12358892 expire?
Our index shows an expiration date of Jul 10, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.